Advertisement

Conquer Cancer Announces 2021 Israel Cancer Research Fund Career Development Award


Advertisement
Get Permission

Conquer Cancer, the ASCO Foundation, is pleased to announce Shlomit Strulov Shachar, MD, of Tel Aviv Sourasky Medical Center, is the recipient of the 2021 Conquer Cancer–Israel Cancer Research Fund (ICRF) Career Development Award.

Dr. Shachar’s proposed study, entitled “Identifying Molecular Oncogenic Drivers Associated With Differential Clinical Benefit to Inhibition of the PI3K Pathway in Estrogen Receptor–Positive Metastatic Breast Cancer,” will focus on identifying mechanisms of drug resistance associated with hormone receptor–positive metastatic breast cancer.

“Treating metastatic breast cancer is a challenge, and this grant will allow us to investigate the mechanism of resistance to systemic therapy and hopefully find the optimal treatment sequencing of hormone receptor–positive metastatic breast cancer,” said Dr. Shachar.

Shlomit Strulov Shachar, MD

Shlomit Strulov Shachar, MD

Beryl Chernov

Beryl Chernov

This is the second year of collaboration between Conquer Cancer and the Israel Cancer Research Fund to award a Career Development Award supporting high-quality clinical oncology research by an early-career physician-scientist in Israel. The Career Development Award is a 3-year, $200,000 grant that provides resources to clinical and translational investigators during their initial years of faculty appointment, when funding is especially challenging to secure. The grant period starts on September 1, 2021.

“ICRF is so pleased to collaborate once again with Conquer Cancer. Together we can fund the research of Dr. Shlomit Strulov Shachar, a deserving early-stage investigator, who will focus on identifying drug resistance in metastatic cancer,” said Beryl Chernov, ICRF National Executive Director. “It is gratifying to partner with an organization such as Conquer Cancer that is also committed to supporting researchers at various levels of career ­development.” 

© 2021. American Society of Clinical Oncology. All rights reserved.

 


Advertisement

Advertisement




Advertisement